INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.

Ingo K. Mellinghoff, Martin J. Van Den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Leigh Clarke, Joe Sammy Mendez, Liam Welsh, Warren P. Mason, Andreas Felix Hottinger, Juan Manuel Sepulveda Sanchez, Wolfgang Wick, Riccardo Soffietti, Steven Schoenfeld, Dan Zhao, Shuchi Sumant Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy Francis Cloughesy; Memorial Sloan Kettering Cancer Center, New York, NY; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Tel Aviv, Israel; Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France; Duke University Medical Center, Durham, NC; University of California, San Francisco, San Francisco, CA; University of Utah, Salt Lake City, UT; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Princess Margaret - University Health Network, Toronto, ON, Canada; Department of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois & Lausanne University, Lausanne, Switzerland; Hospital Universitario 12 Octubre, Madrid, Spain; University of Heidelberg, Heidelberg, Germany; University of Turin, Torino, Italy; Servier Pharmaceuticals, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of California, Los Angeles, CA

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2023, issue of the Journal of Clinical Oncology.
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

Deborah Schrag, Qian Shi, Martin R. Weiser, Marc J Gollub, Leonard B. Saltz, Benjamin Leon Musher, Joel Goldberg, Tareq Al Baghdadi, Karyn A. Goodman, Robert R. McWilliams, Jeffrey M. Farma, Thomas J. George, Hagen Fritz Kennecke, Alan P. Venook, Eileen Mary O’Reilly, Jeffrey A. Meyerhardt, Amylou C. Dueck, Ethan Basch, George J. Chang, Harvey J. Mamon, Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Center, New York, NY; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Colorectal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; SWOG, Portland, OR; Brigham and Women’s Hospital, Boston, MA; IHA Hematology Oncology Consult, Ypsilanti, MI; Mayo Clinic, Rochester, MN; ECOG, Philadelphia, PA; NRG Oncology and The University of Florida Health Cancer Center, Gainesville, FL; Canadian Cancer Trials Group, Kingston, ON, Canada; Alliance for Clinical Trials in Oncology, Chicago, IL; Dana-Farber Cancer Institute, Boston, MA; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; MD Anderson Cancer Center, Houston, TX

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2023, issue of the Journal of Clinical Oncology.
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Roy S. Herbst, Masahiro Tsuboi, Tom John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lu, Wu-Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Marta Stachowiak, Yuri Rukazenkov, Yi-Long Wu; Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT; Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Klinik für Pneumologie - Evangelische Lungenklinik Berlin Buch, Berlin, Germany; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; Department of Oncology, National Cheng Kung University, Tainan, Taiwan; Thoracic Oncology Division, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, South Korea; Ho Chi Minh City Oncology Hospital, Binh Thanh District, Ho Chi Minh City, Viet Nam; Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; Department of Lung Cancer and Thoracic Tumours, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Oncology Biometrics, AstraZeneca, Cambridge, United Kingdom; Late Oncology Research & Development, AstraZeneca, Warsaw, Poland; Oncology Research & Development, AstraZeneca, Cambridge, United Kingdom; Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2023, issue of the Journal of Clinical Oncology.
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

Alex Francisco Herrera, Michael Leo LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, David C. Hodgson, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joo Y Song, Richard F. Little, Brad S. Kahl, John Paul Leonard, Kara M Kelly, Sonali M. Smith, Jonathan W. Friedberg; City of Hope National Medical Center, Duarte, CA; Southwest Oncology Group Statistical Center, Seattle, WA; Emory University School of Medicine, Atlanta, GA; SWOG Cancer Research Network, Seattle, WA; Weill Cornell Medicine, New York, NY; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Research Institute of McGill University Health Centre, Montreal, QC, Canada; SickKids Hospital, Toronto, ON, Canada; Princess Margaret - University Health Network, Toronto, ON, Canada; Tufts Medical Center/Tufts University, Boston, MA; University of Texas MD Anderson Cancer Center, Houston, TX; University of Rochester, Rochester, NY; Washington University School of Medicine, St. Louis, MO; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; Roswell Park Comprehensive Cancer Center and University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY; University of Chicago, Chicago, IL; University of Rochester Medical Center, Rochester, NY

The full, final text of this abstract will be available at meetings.asco.org on the day of presentation and in the online supplement to the June 10, 2023, issue of the Journal of Clinical Oncology.